1 ASX 200 share to buy before an effective COVID vaccine announcement

The whole world is waiting on an effective COVID vaccine. But once it's announced this ASX 200 share won't be the bargain it is today.

The whole world is waiting on an effective COVID vaccine. But if and when a proven vaccine arrives, the Flight Centre Travel Group Ltd (ASX: FLT) share price likely won't be the bargain it is today.

Like most travel related shares – such as Webjet Limited (ASX: WEB) and Sydney Airport Holdings Pty Ltd (ASX: SYD) – Flight Centre's share price was particularly hard hit from the fallout of the coronavirus.

From 21 February through to 19 March shares tumbled 75%. Flight Centre's share price is up 52% since that low, but remains down 66% year-to-date.

By comparison the S&P/ASX 200 Index (ASX: XJO) is down 8% in 2020.

Macquarie shre price asx share price opportunity represented by road sign saying opportunity ahead

Image source: Getty Images

What does Flight Centre Travel Group do?

Flight Centre is one of the world's largest travel agency groups. Its company-owned operations span more than 23 countries and its corporate travel management network covers more than 90 countries.

The company has a broad range of brands across its corporate, leisure and destination segments. These include Student Flights, Travel Money Oz, Corporate Traveller and Topdeck.

Flight Centre shares first began trading on the ASX in 1995.

Why buy shares in Flight Centre before a vaccine is proven?

As Benjamin Franklin famously quipped, "In this world, nothing is certain except death and taxes."

So too, we can't be certain that the world's scientists will produce a highly effective vaccine to squash COVID-19 from our lives. But there are tremendous incentives for the leading pharmaceutical companies to do so. And they're backed by unprecedented funding, cutting edge technology, and some of the best minds in the world.

So, while nothing is certain, I believe we'll see a series of vaccines rolled out over the coming 12–24 months. The initial ones may only be 50% effective, as some clinical trials are already reporting. That's a big step in the right direction, but not enough to reopen global travel. Or rejuvenate Flight Centre's revenues and share price to early 2020 levels.

However, with time, the results will almost certainly improve. Remember, this global race for an effective vaccine only kicked off 7 months ago.

But the vast majority of investors don't look ahead 2 or more years. They wait until good news is locked in and then invest, along with everyone else.

In this case the good news is a proven vaccine. And that news will likely trickle out over a period of months as it progresses through various trials. And with each new successful announcement leading ASX travel and leisure shares are likely to see renewed investor interest. Which is why, by the time such a vaccine is approved and in mass production, the biggest gains to be had from these shares will already be history.

As mentioned up top, Flight Centre's share price is still down 66% from 2 January's $39.52 per share. In my opinion, there's no reason shares couldn't be trading for $39.52 again once air travel returns to its pre-pandemic levels.

If they do, that would represent a 190% share price gain from yesterday's closing price of $13.61. Should that eventuate, I imagine that's worth waiting a few years for things to play out.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Webjet Ltd. The Motley Fool Australia has recommended Flight Centre Travel Group Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A geeky-looking young man with glasses bites down onto a computer keyboard in frustration or despair.
ASX Share Market News

Tech shares led the ASX 200 amid NVIDIA scandal and Microsoft outage last week

Xero's 1H FY27 results and a strong lead from Wall Street pushed the tech sector higher.

Read more »

Piles of increasing coins alongside an hourglass.
Opinions

Why I'm planning to buy more Soul Patts shares in 2027

I think Soul Patts is a great long-term buy.

Read more »

a close up of a woman's face looks skywards as she is showered in a sea of graphic symbols of gold and silver coins bearing the bitcoin logo.
Cryptocurrencies

Are you a 'greater fool' for owning Bitcoin?

Is Bitcoin truly an investment?

Read more »

IPO written in purple on blocks on top of each other in the air.
IPOs

Anthropic IPO: Are 5 types of shares too many?

Anthropic is going for a very unusual setup.

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Broker Notes

Buy, hold, sell: Resmed, Goodman Group, CBA shares

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities.

Read more »

colleagues on a lunch break looking at iPhone
Broker Notes

Top brokers name 3 ASX shares to buy now

Here's what brokers are recommending as buys this week.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
ASX Share Market News

5 things to watch on the ASX 200 on Friday

Will Friday the 13th be unlucky for the share market?

Read more »